ADVERTISEMENT
First-Line Brentuximab Vedotin Plus Chemotherapy Improves OS in Classical Hodgkin Lymphoma
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses results from the ECHELON-1 trial, which found that brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) treatment resulted in a statistically significant reduction in the risk of death compared to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), with a manageable safety profile, among patients with stage III/IV classical Hodgkin lymphoma.
This interview was conducted at the 2022 ASCO Annual Meeting.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Current Issue
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Subscribe
Advertisement
Advertisement
Advertisement
Recent Stories
Advertisement